Avicanna Dirección

Dirección controles de criterios 2/4

El CEO de Avicanna's es Aras Azadian , nombrado en Jan 2016, tiene una permanencia de 8.25 años. compensación anual total es CA$485.78K, compuesta por 33.1% salario y 66.9% primas, incluidas acciones y opciones de la empresa. posee directamente un 3.64% de las acciones de la empresa, por valor de €920.51K. La antigüedad media del equipo directivo y de la junta directiva es de 1.3 años y 4.2 años, respectivamente.

Información clave

Aras Azadian

Chief Executive Officer (CEO)

CA$485.8k

Compensación total

Porcentaje del salario del CEO	33.1%
Permanencia del CEO	8.3yrs
Participación del CEO	3.6%
Permanencia media de la dirección	1.4yrs
Promedio de permanencia en la Junta Directiva	4.3yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Aras Azadian en comparación con los beneficios de Avicanna?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	-CA$9m
Sep 30 2023	n/a	n/a	-CA$12m
Jun 30 2023	n/a	n/a	-CA$14m
Mar 31 2023	n/a	n/a	-CA$16m
Dec 31 2022	CA$486k	CA$161k	-CA$15m
Sep 30 2022	n/a	n/a	-CA$16m
Jun 30 2022	n/a	n/a	-CA$16m
Mar 31 2022	n/a	n/a	-CA$15m
Dec 31 2021	CA$244k	CA$127k	-CA$17m
Sep 30 2021	n/a	n/a	-CA$24m
Jun 30 2021	n/a	n/a	-CA$29m
Mar 31 2021	n/a	n/a	-CA$34m
Dec 31 2020	CA$358k	CA$110k	-CA$33m
Sep 30 2020	n/a	n/a	-CA$25m
Jun 30 2020	n/a	n/a	-CA$24m
Mar 31 2020	n/a	n/a	-CA$21m
Dec 31 2019	CA$608k	CA$240k	-CA$22m
Sep 30 2019	n/a	n/a	-CA$18m
Jun 30 2019	n/a	n/a	-CA$14m
Mar 31 2019	n/a	n/a	-CA$11m
Dec 31 2018	CA$150k	CA$150k	-CA$7m
Sep 30 2018	n/a	n/a	-CA$5m
Dec 31 2017	CA$180k	CA$150k	-CA$3m

Compensación vs. Mercado: La compensación total ($USD355.08K) de Aras está en línea con el promedio de empresas de tamaño similar en el mercado German ($USD406.04K).

Compensación vs. Ingresos: La compensación de Aras ha aumentado mientras la empresa no es rentable.

CEO

Aras Azadian

8.3yrs

Permanencia

CA$485,778

Compensación

Mr. Aras Azadian, M. Mgmt, Msc Management, B.Econ, MBA, is a Co-Founder of Avicanna Inc. He serves as Chief Executive Officer and Director since November 25, 2016 of Avicanna Inc. and served as its Chairma...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Aras Azadian	Co-Founder	8.3yrs	CA$485.78k	3.64% CA$ 760.1k
Phillip Cardella	Chief Financial Officer	1.4yrs	CA$265.80k	0.46% CA$ 96.8k
Frantz Devedec	Executive Vice President of Research & Development	no data	CA$227.33k	sin datos
Stephen Kim	Chief Legal Officer & General Counsel of Avicanna USA Inc.	1.4yrs	CA$423.34k	sin datos
Arash Moghani	Executive Vice President of Operations & Technology	no data	sin datos	sin datos
Ingrid Diaz	VP, Assistant General Counsel & Corporate Compliance Officer	less than a year	sin datos	sin datos
Ivana Maric	Executive Vice President of Marketing	no data	sin datos	sin datos
Enric Pujol	Vice President of People	no data	sin datos	sin datos
Carlos Enrique Muete	SVP of Clinical Development	no data	sin datos	sin datos
Karolina Urban	Executive Vice President of Scientific & Medical Affairs	less than a year	sin datos	sin datos

1.4yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de 0NN no se considera experimentado ( 1.3 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Aras Azadian	Co-Founder	7.5yrs	CA$485.78k	3.64% CA$ 760.1k
Sheldon Inwentash	Member of Business Advisory Board	no data	sin datos	5.36% CA$ 1.1m
Daniel Sauder	Member of Global Scientific Advisory Board	no data	sin datos	sin datos
Giancarlo Char	Director	5.6yrs	CA$94.48k	0.24% CA$ 49.9k
Aline Masuda	Member of Business Advisory Board	no data	sin datos	sin datos
Mauricio Torres-Pradilla	Member of Global Scientific Advisory Board	no data	sin datos	sin datos
Humberto Reynales	Member of International Scientific Advisory Board	no data	sin datos	sin datos
Max Jones	Member of Global Scientific Advisory Board	no data	sin datos	sin datos
John McVicar	Independent Director	2.9yrs	CA$97.10k	0.28% CA$ 59.2k
Eileen McCormack	Independent Director	2.3yrs	CA$75.98k	0.072% CA$ 15.1k
Ori Tal	Member of Business Advisory Board	no data	sin datos	sin datos
Al Harrington	Member of Business Advisory Board	no data	sin datos	sin datos

4.3yrs

Permanencia media

Junta con experiencia: La junta directiva de 0NN se considera experimentada (4.2 años de antigüedad promedio).

Avicanna Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Less than half of directors are independent

Avicanna Announces Appointment of Paul Fornazzari to Board of Directors

Avicanna Inc. Announces Retirement of Chandra Panchal, PhD from the Board of Directors

Insider recently bought €90k worth of stock

Avicanna LATAM S.A.S. Announces Step Down of Lucas Nosiglia as President, Effective January 31, 2023

Insider recently bought €388k worth of stock

Recent updates

Avicanna Inc. announced that it has received CAD 2.125584 million in funding

Avicanna Inc. Announces Completion of Topical Gel Observational Real-World Evidence Study

Full year 2023 earnings released: CA$0.10 loss per share (vs CA$0.25 loss in FY 2022)

Avicanna Inc Announces the Canadian Launch of 10% CBD (THC Free) Proprietary Formulation

Avicanna Inc. to Report Fiscal Year 2023 Results on Apr 01, 2024

Avicanna Inc. Obtains Its First Indication-Specific Drug Registration with Trunerox

Avicanna Inc. announced that it has received CAD 0.888128 million in funding

Less than half of directors are independent

Third quarter 2023 earnings released: CA$0.016 loss per share (vs CA$0.048 loss in 3Q 2022)

Avicanna Announces Appointment of Paul Fornazzari to Board of Directors

Avicanna Inc. to Report Q3, 2023 Results on Nov 14, 2023

Avicanna Inc. Provides Update on the Successful Launch of MyMedi.ca

Avicanna Inc. Announces Retirement of Chandra Panchal, PhD from the Board of Directors

Second quarter 2023 earnings released: CA$0.021 loss per share (vs CA$0.08 loss in 2Q 2022)

Avicanna Inc. announced that it has received CAD 1.455 million in funding

Avicanna Inc. (TSX:AVCN) completed the acquisition of Medical Cannabis by Shoppers Drug Mart Inc from Shoppers Drug Mart Inc.

Avicanna Inc. (TSX:AVCN) entered into definitive Asset Purchase Agreement to acquire Medical Cannabis by Shoppers Drug Mart Inc from Shoppers Drug Mart Inc. for CAD 2.6 million.

First quarter 2023 earnings released: CA$0.033 loss per share (vs CA$0.02 loss in 1Q 2022)

Insider recently bought €90k worth of stock

Avicanna LATAM S.A.S. Announces Step Down of Lucas Nosiglia as President, Effective January 31, 2023

Avicanna Inc. announced that it has received CAD 1.769097 million in funding

Avicanna and Santé Cannabis Initiate Real-World Evidence Study on Musculoskeletal Pain and Inflammation with the Rho Phytotm Cbg Transdermal Gel Topical Product

Avicanna Inc. Commercializes ‘Influid’, a Proprietary Water-soluble technology in the Canadian Market

Insider recently bought €388k worth of stock

Third quarter 2022 earnings released: CA$0.048 loss per share (vs CA$0.065 loss in 3Q 2021)

Third quarter 2022 earnings released: CA$0.048 loss per share (vs CA$0.065 loss in 3Q 2021)

Avicanna Inc. announced that it has received CAD 0.626763 million in funding

Avicanna Files Complete Patent Specifications Relating to A Novel Cannabinoid Formulation for Reducing Incidence of Seizures and Sudden Unexpected Death in Epilepsy

Avicanna Introduces a New Medical Cannabis Education Online Portal, "Avicenna Academy" for Health Care Professionals

Assad Kazeminy Retires as Director of Avicanna Inc

Second quarter 2022 earnings released: CA$0.08 loss per share (vs CA$0.067 loss in 2Q 2021)

Avicanna Inc. announced that it has received CAD 2.782302 million in funding

Avicanna Inc., Annual General Meeting, Aug 31, 2022

An unknown buyer acquired 63 percent stake in Sativa Nativa S.A.S. from Avicanna Inc. (TSX:AVCN) for CAD 0.81 million.

Forecast to breakeven in 2024

First quarter 2022 earnings released: CA$0.02 loss per share (vs CA$0.085 loss in 1Q 2021)

Avicanna Inc. Announces Chief Financial Officer Changes

Avicanna Inc. announced that it has received CAD 1.473826 million in funding from Ei.Ventures, Inc.

Full year 2021 earnings released: CA$0.41 loss per share (vs CA$1.12 loss in FY 2020)

Avicanna Inc. announced that it has received CAD 2.523568 million in funding

Avicanna Inc. Provides Consolidated Revenue Guidance for the Fourth Quarter, Full Year 2021 and Full Year 2022

Avicanna Inc. announced that it expects to receive CAD 1.3008 million in funding

Forecast to breakeven in 2024

Avicanna Inc. Launches Its Clinically Backed CBD Derma-Cosmetics Brand, Pura H&W, in the United States in Partnership with Red White and Bloom

Avicanna and Harrington Wellness Launch Re+Play™ Branded Cbd Topicals Products in Canada

Avicanna Inc. Files Patent to Protect its Advanced Oral Cannabinoid Platform and its Applications for Neurological Diseases

Third quarter 2021 earnings released: CA$0.065 loss per share (vs CA$0.25 loss in 3Q 2020)

Insider recently bought €59k worth of stock

Avicanna Files US Patent Application for a Novel Cannabinoid Formulation in Reducing Incidence of Seizures and Sudden Unexpected Death in Epilepsy

Less than half of directors are independent

Second quarter 2021 earnings released: CA$0.067 loss per share (vs CA$0.31 loss in 2Q 2020)

Avicanna Inc. announced that it has received CAD 2.118 million in funding

Avicanna Inc. announced that it expects to receive CAD 2 million in funding

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Miembros de la Junta

Permanencia media